Storm Therapeutics presented Phase 1 sarcoma data for its first-in-class METTL3 inhibitor STC-15 at ASCO 2026.
STORM Therapeutics is a clinical biotechnology company creating novel therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases
STORM Therapeutics is a clinical biotechnology company creating novel therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. Their lead product, STC-15, is the first RNA modifying enzyme inhibitor to enter human clinical development.